Table 2.
Distribution of biomarkers across different TNBC molecular subtypes.
| Predictive Biomarker | Study | Total Number (N) | BL-Related | LAR | Mesenchymal- Related | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BL | BLIA-IM | BLIS | BL1 | BL2 | LAR | M | MSL-MES | |||
| PD-L1 positivity | ||||||||||
| Percentage of PD-L1 positivity |
Sood et al. [41] | |||||||||
| N = 119 | 18/28 (64%) |
- | - | - | - | 8/34 (24%) |
- | 15/57 (26%) |
||
| Alves et al. [42] | ||||||||||
| N = 57 | - | 11/33 (33%) |
1/21 (4.7%) |
- | - | 0/2 (0%) |
- | 0/1 (0%) |
||
| Phase III IMpassion 130 [29] | ||||||||||
| N = 836 | - | 167/226 (74%) |
112/351 (32%) |
- | - | 67/217 (31%) |
- | 12/42 (28%) |
||
| Phase III NeoTRIPaPDL1 [32] | ||||||||||
| N = 227 | - | - | - | 64/82 (78%) |
11/19 (58%) |
12/34 (35%) |
17/56 (31%) |
23/36 (65%) |
||
| Phase II FUTURE [36] | ||||||||||
| N = 19 | - | 13/19 (67%) |
- | - | - | - | - | - | ||
| Phase II Pembrolizumab + Enobosarm [40] | ||||||||||
| N = 16 | - | - | - | - | - | 2/16 (12.5%) |
- | - | ||
| Tumor mutational burden | ||||||||||
| TMB (mut/Mb) | Lehmann et al. [9] | |||||||||
| N = 183 | - | - | - | N = 64 (2.1 mut/Mb) |
N = 37 (1.2 mut/Mb) |
N = 28 (1.8 mut/Mb) |
N = 54 (2.3 mut/Mb) |
- | ||
| Tumor infiltrating lymphocytes rate | ||||||||||
| Percentage of TILs | Lehmann et al. [13] | |||||||||
| N = 167 | - | N = 36 (TILs: 38%) |
- | N = 34 (TILs: 15%) |
N = 17 (TILs: 23%) |
N = 18 (TILs: 17%) |
N = 40 (TILs: 9%) |
N = 22 (TILs: 21%) |
||
| Distribution of spatial immunophenotype | ||||||||||
| Percentage of each immunophenotype | Bareche et al. [15] | |||||||||
| FI (%) | N = 697 | 15/162 (9%) |
138/181 (76%) |
- | - | - | 11/124 (9%) |
0/141 (0%) |
19/89 (21%) |
|
| SR (%) | 126/162 (78%) |
41/181 (22%) |
- | - | - | 26/124 (21%) |
9/141 (6%) |
4/89 (4.4%) |
||
| MR (%) | 21/162 (13%) |
2/181 (1%) |
- | - | - | 87/124 (70%) |
132/141 (93%) |
66/89 (74%) |
||
| Percentage of each immunophenotype | Gruosso et al. [43] | |||||||||
| FI (%) | N = 31 | - | 5/11 (46%) |
- | 1/8 (12.5%) |
1/2 (50%) |
0/3 (0%) |
0/6 (0%) |
0/1 (0%) |
|
| SR (%) | - | 4/11 (36%) |
- | 5/8 (62.5%) |
0/2 (0%) |
1/3 (33%) |
0/6 (0%) |
1/1 (100%) |
||
| MR (%) | - | 2/11 (18%) |
- | 2/8 (25%) |
1/2 (50%) |
1/3 (33%) |
4/6 (67%) |
0/1 (0%) |
||
| ID (%) | - | 0/11 (0%) |
- | 0/8 (0%) |
0/2 (0%) |
1/3 (33%) |
2/6 (33%) |
0/1 (0%) |
||
| Percentage of each immunophenotype | Lehmann et al. [9] | |||||||||
| FI (%) | N = 183 | - | - | - | 14/64 (22%) |
9/37 (24%) |
5/28 (18%) |
1/54 (2%) |
- | |
| SR (%) | - | - | - | 28/64 (44%) |
10/37 (27%) |
8/28 (29%) |
4/54 (7%) |
- | ||
| MR (%) | - | - | - | 17/64 (27%) |
10/37 (27%) |
12/28 (43%) |
22/54 (41%) |
- | ||
| ID (%) | - | - | - | 5/64 (8%) |
8/37 (22%) |
3/28 (11%) |
27/54 (50%) |
- | ||
| Immune signature prevalence | ||||||||||
| Percentage of immune-hot GSIS signature | Phase II Carbo + Nabpaclitaxel [44] | |||||||||
| N = 58 | - | 16/16 (100%) |
- | 5/11 (45%) |
2/5 (40%) |
1/7 (14%) |
0/15 (0%) |
1/4 (25%) |
||
| CD274 amplification rate | ||||||||||
| Percentage of CD274 amplification | Lehmann et al. [9] | |||||||||
| N = 183 | - | - | - | 6/64 (9%) |
2/37 (5%) |
2/28 (7%) |
6/54 (11%) |
- | ||
Abbreviations. BL: basal-like, BLIA: basal-like immune-activated, BLIS: basal-like immune-suppressed, GSIS: GeparSixto immune gene expression signature, IM: immunomodulatory, LAR: luminal androgen receptor, M: mesenchymal, MES: mesenchymal, MSL: mesenchymal stem-like, PD-L1: programmed death-ligand 1, TILs: tumor infiltrating lymphocytes, TMB: tumor mutational burden.